The term LOC643862 Inhibitors refers to a specialized class of chemical compounds strategically designed to modulate the activity of LOC643862, a molecular target currently under scientific investigation. These inhibitors are meticulously crafted through principles rooted in medicinal chemistry, with a primary focus on selectively interfering with the normal functions of LOC643862 within cellular processes. The structural features of LOC643862 Inhibitors undergo a rigorous optimization process, often involving computational modeling and structure-activity relationship studies, to ensure their molecular configurations are finely tuned for precise binding to the target.
The significance of LOC643862 Inhibitors lies in their potential to disrupt the biochemical activities associated with LOC643862, a molecular entity believed to play a role in various biological pathways. Researchers in this field delve into the three-dimensional structure of LOC643862 and its binding interactions with inhibitors, aiming to unravel the intricate molecular mechanisms underlying inhibition. The study of LOC643862 Inhibitors contributes to a broader understanding of cellular processes, offering insights into the roles played by LOC643862 in diverse biological pathways and expanding our knowledge of the regulatory networks governing cellular activities. This research not only advances our comprehension of the molecular intricacies surrounding LOC643862 but also contributes to the broader scientific understanding of molecular targets and their involvement in fundamental cellular functions.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib inhibits CDK4 and CDK6, which may reduce the activity of proteins like Speedy/RINGO that are involved in the cell cycle, thereby potentially reducing its expression. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
Flavopiridol inhibits various CDKs and could decrease the expression of cell cycle regulatory proteins by interrupting the cell cycle progression. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Roscovitine is a CDK inhibitor that may affect the expression of cell cycle proteins by halting the cycle at specific checkpoints. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is a selective inhibitor of CDKs and could potentially downregulate proteins that regulate the cell cycle through CDK modulation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Sirolimus targets mTOR, which is involved in cell cycle progression, and might indirectly affect the expression of cell cycle regulators. | ||||||
Aphidicolin | 38966-21-1 | sc-201535 sc-201535A sc-201535B | 1 mg 5 mg 25 mg | $82.00 $300.00 $1082.00 | 30 | |
Aphidicolin is a DNA polymerase inhibitor, which can lead to S-phase arrest, possibly affecting the levels of proteins involved in cell cycle regulation. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
Camptothecin inhibits DNA topoisomerase I, leading to DNA damage and potential downregulation of cell cycle regulatory proteins. | ||||||
Mitoxantrone | 65271-80-9 | sc-207888 | 100 mg | $279.00 | 8 | |
Mitoxantrone intercalates DNA and inhibits topoisomerase II, which may impact the expression of cell cycle-related proteins. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $32.00 $170.00 $385.00 | 63 | |
Etoposide inhibits topoisomerase II, potentially causing DNA damage and affecting the expression of proteins that regulate the cell cycle. | ||||||
Vinblastine | 865-21-4 | sc-491749 sc-491749A sc-491749B sc-491749C sc-491749D | 10 mg 50 mg 100 mg 500 mg 1 g | $100.00 $230.00 $450.00 $1715.00 $2900.00 | 4 | |
Vinblastine disrupts microtubule formation, potentially altering the mitotic spindle and affecting the expression of mitosis-related cell cycle proteins. | ||||||